U · A
Unknown Author
January 24, 2026
Latham Advises Intuitive Ventures on Amber Therapeutics’ US$100 Million Series A
1 min
AI-made summary
- Latham & Watkins advised Intuitive Ventures in the US$100 million Series A funding round for Amber Therapeutics, a London-based medical technology company focused on adaptive neuromodulation therapy for mixed urinary incontinence
- The funding round was led by New Enterprise Associates, with participation from Intuitive Ventures, F-Prime Capital, Lightstone Ventures, and existing investors Oxford Science Enterprises and 8VC
- The Latham team was led by partners Shing Lo and Jim Morrone, with associate Beatrice Leung.
Latham & Watkins has advised Intuitive Ventures on its participation in the US$100 million Series A funding round of Amber Therapeutics, a London-based med tech company developing breakthrough adaptive neuromodulation therapy to treat mixed urinary incontinence. The round was led by New Enterprise Associates, with participation from Intuitive Ventures, F-Prime Capital, and Lightstone Ventures, alongside existing investors Oxford Science Enterprises and 8VC. The Latham team was led by London corporate partner Shing Lo and Bay Area partner Jim Morrone, with associate Beatrice Leung.~~
U
Article Author
Unknown Author
The Sponsor